Archer

ArcherDX is a leading genomics company focused on democratizing precision oncology through its proprietary Anchored Multiplex PCR (AMP) technology. The company develops highly sensitive and specific next-generation sequencing (NGS) assays to detect gene fusions, point mutations, and copy number variations across various cancer types. Its portfolio includes the STRATAFIDE DX and Personalized Cancer Monitoring (PCM) platforms, which support both liquid biopsy and tissue-based testing for therapy optimization and minimal residual disease (MRD) detection. ArcherDX was acquired by Invitae in 2020 for approximately $1.4 billion to integrate somatic mutation profiling with germline testing. In 2022, its core NGS assets were subsequently acquired by Integrated DNA Technologies (IDT), where the technology continues to be a cornerstone of precision oncology research and clinical diagnostics.